Faculty, Staff and Student Publications
Publication Date
8-1-2024
Journal
International Journal of Hematology
DOI
10.1007/s12185-024-03787-z
PMID
38748089
PMCID
PMC11809101
PubMedCentral® Posted Date
8-1-2025
PubMedCentral® Full Text Version
Author MSS
Abstract
Study aims: To evaluate the outcomes of patients with 3q26.2/MECOM-rearranged chronic myeloid leukemia (CML).
Methods: We reviewed consecutive adult patients with 3q26.2/MECOM-rearranged CML between January 1, 1998 and February 16, 2023. Rearrangements of 3q26.2/MECOM were confirmed by conventional cytogenetics, and fluorescence in situ hybridization starting in 2015.
Results: We identified 55 patients with MECOM-rearranged CML, including 23 in chronic phase (CP) or accelerated phase (AP) and 32 in blast phase (BP). Nine patients (16%) achieved a major cytogenetic response (MCyR) or deeper. At a median follow-up of 89 months, median survival was 14 months. The 5-year survival rate was 19% overall, 23% in CML-CP/AP, and 15% in CML-BP. In the 6-month landmark analysis, the 5-year survival rate was 41% for allogeneic stem cell transplantation (allo-SCT) recipients versus 17% for non-recipients (P = 0.050). Multivariate analysis showed that the percentage of marrow blasts and achievement of MCyR or deeper could predict survival.
Conclusion: Outcomes of 3q26.2/MECOM-rearranged CML are poor despite the availability of multiple BCR::ABL1 tyrosine kinase inhibitors (TKIs). Third-generation TKIs in combination with novel agents and possible allo-SCT could be considered given the poor outcomes and resistance to second-generation TKIs.
Keywords
Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Young Adult, Chromosomes, Human, Pair 3, Follow-Up Studies, Gene Rearrangement, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Retrospective Studies, Survival Rate, Treatment Outcome, Chronic myeloid leukemia, MECOM, tyrosine kinase inhibitors, stem cell transplant
Published Open-Access
yes
Recommended Citation
Akiyama, Hiroki; Kantarjian, Hagop; Jabbour, Elias; et al., "Outcome of 3q262/MECOM Rearrangements in Chronic Myeloid Leukemia" (2024). Faculty, Staff and Student Publications. 4537.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4537
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons